Clinical trials demonstrate that psychedelic-assisted therapy can improve mental health outcomes; however, few studies have recruited sexually diverse samples or reported information on sexual identity.
Aims:
The purpose of this analysis was to examine the relationship between hallucinogen use and mental health outcomes with respect to sexual identity.
Methods:
We conducted a cross-sectional analysis using data from the 2021 National Survey on Drug Use and Health to examine the relationship between hallucinogen use and psychological distress.
Results:
In a sample representative of 253,824,662 U.S. adults, the majority was heterosexual (92%), aged 50–64 (25%), women (51%), non-Hispanic White (62%), college educated (31%), and had an annual household income of $75,000 or higher (39%). The majority reported no lifetime hallucinogen use (82%) and no past month severe psychological distress (93%). Sexual identity modified the relationship between hallucinogen use and psychological distress. After stratifying by sexual identity and adjusting for covariates, hallucinogen use was associated with reduced odds of psychological distress in the heterosexual population (OR = 0.76, 95% CI: 0.59, 0.96) but the relationship was not significant in the sexual minority population.
Conclusion:
We found that in a nationally representative sample, psychedelic use was associated with reduced odds of psychological distress in heterosexual individuals only. Future research should investigate why hallucinogen use was not protective in sexual minority groups given their disproportionate burden of poor mental health outcomes.
AndersonBTDanforthADaroffPR, et al. (2020) Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine27: 100538.
2.
ArgentoEStrathdeeSATupperK, et al. (2017) Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalized women in a Canadian setting. BMJ Open7: e016025.
3.
ArgentoEBraschelMWalshZ, et al. (2018) The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. J Psychopharmacol (Oxford, England)32: 1385–1391.
ChaudoirSRWangKPachankisJE (2017) What reduces sexual minority stress? A review of the intervention “toolkit.”J Soc Iss73: 586–617.
10.
ChingTHW (2020) Intersectional insights from an MDMA-assisted psychotherapy training trial: An open letter to racial/ethnic and sexual/gender minorities. J Psyched Stud4: 61–68.
FeducciaAAJeromeLYazar-KlosinskiB, et al. (2019) Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry10: 650.
13.
Garcia-RomeuABarrettFSCarbonaroTM, et al. (2021) Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. J Psychopharmacol (Oxford, England)35: 353–361.
14.
GeorgeJRMichaelsTISeveliusJ, et al. (2020) The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion. J Psyched Stud4: 4–15.
15.
GoodwinGMAaronsonSTAlvarezO, et al. (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med387: 1637–1648.
16.
GreenKEFeinsteinBA (2012) Substance use in lesbian, gay, and bisexual populations: An update on empirical research and implications for treatment. Psychol Addict Behav26: 265–278.
17.
GriffinMCallanderDDuncanDT, et al. (2020) Differential risk for drug use by sexual minority status among electronic dance music party attendees in New York City. Subst Use Misuse55: 230–240.
18.
GriffithsRRJohnsonMWCarducciMA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol (Oxford, England)30: 1181–1197.
19.
HealDJSmithSLBelouinSJ, et al. (2023) Psychedelics: Threshold of a therapeutic revolution. Neuropharmacology236: 109610.
HendricksPSThorneCBClarkCB, et al. (2015b) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol (Oxford, England)29: 280–288.
22.
HullTDMalgaroliMGazzaleyA, et al. (2022) At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. J Affect Disord314: 59–67.
23.
JonesGRicardJALipsonJ, et al. (2022) Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Scient Rep12: 4099.
24.
JonesGM (2023) Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes. J Psychopharmacol (Oxford, England)37: 61–69.
25.
JonesGMNockMK (2022a) Exploring protective associations between the use of classic psychedelics and cocaine use disorder: A population-based survey study. Scient Rep12: 2574.
26.
JonesGMNockMK (2022b) Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. J Psychopharmacol (Oxford, England)36: 57–65.
27.
JonesGMNockMK (2022c) MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J Psychopharmacol (Oxford, England)36: 46–56.
28.
JonesGMNockMK (2022d) Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. Scient Rep12: 16976.
29.
KingMSemlyenJTaiSS, et al. (2008) A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people. BMC Psychiatry8: 70.
30.
KopraEIFerrisJAWinstockAR, et al. (2023) Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. J Psychopharmacol (Oxford, England)37: 733–748.
31.
KrebsTSJohansenP-Ø (2013) Psychedelics and mental health: a population study. PloS One8: e63972.
32.
LearyTLitwinGHMetznerR (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Mental Dis137: 561–573.
33.
MalikMHIqbalSNomanM, et al. (2023) Mental health disparities among homosexual men and minorities: A systematic review. Am J Mens Health17: 15579883231176646.
34.
MartinsDBarrattMJPiresCV, et al. (2017) The detection and prevention of unintentional consumption of DOx and 25x-NBOMe at Portugal’s Boom Festival. Hum Psychopharmacol32: e2608.
35.
MeanleySHaberlenSAOkaforCN, et al. (2020) Lifetime exposure to conversion therapy and psychosocial health among midlife and older adult men who have sex with men. Gerontol60: 1291–1302.
36.
MeyerIH (2003) Prejudice, social stress, and mental health in lesbian, gay, and bisexual populations: Conceptual issues and research evidence. Psychol Bull129: 674–697.
37.
MichaelsTIPurdonJCollinsA, et al. (2018) Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry18: 245.
38.
MitchellJMBogenschutzMLiliensteinA, et al. (2021) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med27: 1025–1033.
39.
MoonzweLSSchensulJJKostickKM (2011) The role of MDMA (Ecstasy) in coping with negative life situations among urban young adults. J Psychoact Drugs43: 199–210.
40.
PalmerMMaynardOM (2022) Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience. Harm Reduct J19: 81.
41.
PisanoVDPutnamNPKramerHM, et al. (2017) The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol (Oxford, England)31: 606–613.
42.
PompiliMLesterDForteA, et al. (2014) Bisexuality and suicide: A systematic review of the current literature. J Sex Med11: 1903–1913.
43.
RamirezJLPaz GalupoM (2019) Multiple minority stress: The role of proximal and distal stress on mental health outcomes among lesbian, gay, and bisexual people of color. J Gay Lesbian Mental Health23: 145–167.
44.
RobertsLMChristensBD (2021) Pathways to well-being among LGBT adults: Sociopolitical involvement, family support, outness, and community connectedness with race/ethnicity as a moderator. Am J Commun Psychol67: 405–418.
45.
RosnerBNeicunJYangJC, et al. (2021) Substance use among sexual minorities in the US—Linked to inequalities and unmet need for mental health treatment? Results from the National Survey on Drug Use and Health (NSDUH). J Psychiatr Res135: 107–118.
46.
SaleemiSPennybakerSJWooldridgeM, et al. (2017) Who is “Molly”? MDMA adulterants by product name and the impact of harm-reduction services at raves. J Psychopharmacol (Oxford, England)31: 1056–1060.
47.
SinghADandonaASharmaV, et al. (2023) Minority stress in emotion suppression and mental distress among sexual and gender minorities: A systematic review. Ann Neurosci30: 54–69.
48.
SobuleRIthmanM (2023) Ketamine: Studies show benefit. Missouri Med120: 29–30.
49.
StaufferCSBrownMRAdamsD, et al. (2022) MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials. Front Psychiatry13: 932605.
50.
Substance Abuse and Mental Health Services Administration (2023) Lesbian, gay, and bisexual behavioral health: Results from the 2021 and 2022 National Surveys on Drug Use and Health (SAMHSA Publication No. PEP23-07-01-001). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Available at: https://www.samhsa.gov/data/report/LGB-Behavioral-Health-Report-2021-2022 (accessed 26 July 2023).
Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality (2023a) 2021 National Survey on Drug Use and Health (NSDUH) Methodological Resource Book, Section 13: Statistical inference report. Substance Abuse and Mental Health Services Administration. Available at: https://www.samhsa.gov/data/sites/default/files/reports/rpt41913/2021NSDUHmrbStatInference.pdf (accessed 23 July 2023).
53.
Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality (2023b) 2023 National Survey on Drug Use and Health (NSDUH): Final In-Person Specifications for Programming (English Version). Rockville, MD. Available at: https://www.samhsa.gov/data/report/nsduh-2023-questionnaire (accessed 6 October 2023).
54.
ThrulJGarcia-RomeuA (2021) Whitewashing psychedelics: Racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs Educ Prevent Policy28: 211–214.
55.
TropeAAndersonBTHookerAR, et al. (2019) Psychedelic-assisted group therapy: A systematic review. J Psychoact Drugs51: 174–188.
56.
van der MeerPBFuentesJJKapteinAA, et al. (2023) Therapeutic effect of psilocybin in addiction: A systematic review. Front Psychiatry14: 1134454.
57.
VatchevaKPLeeMMcCormickJB, et al. (2016) Multicollinearity in regression analyses conducted in epidemiologic studies. Epidemiology (Sunnyvale, Calif.)6: 227.
58.
ViñaSM (2024) Minorities’ diminished psychedelic returns: Income and educations impact on Whites, Blacks, Hispanics, and Asians. J Racial Ethnic Health Disparit. Epub ahead of print 16May2024. DOI: 10.1007/s40615-024-02023-y.
WilliamsMTDavisAKXinY, et al. (2021) People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs (Abingdon, England)28: 215–226.
61.
ZeifmanRJYuDSinghalN, et al. (2022) Decreases in suicidality following psychedelic therapy: A meta-analysis of individual patient data across clinical trials. J Clin Psychiatry83: 21r14057.
